TG Therapeutics Inc (NASDAQ: TGTX) on Monday, soared 4.55% from the previous trading day, before settling in for the closing price of $23.31. Within the past 52 weeks, TGTX’s price has moved between $6.52 and $26.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 2506.46% over the last five years. The company achieved an average annual earnings per share of -41.65%. With a float of $137.98 million, this company’s outstanding shares have now reached $151.42 million.
The firm has a total of 264 workers. Let’s measure their productivity. In terms of profitability, gross margin is 92.69%, operating margin of 29.37%, and the pretax margin is 27.62%.
TG Therapeutics Inc (TGTX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of TG Therapeutics Inc is 10.88%, while institutional ownership is 59.36%. The most recent insider transaction that took place on Jun 20 ’24, was worth 275,791. In this transaction Director of this company sold 16,348 shares at a rate of $16.87, taking the stock ownership to the 105,195 shares. Before that another transaction happened on Jun 17 ’24, when Company’s Director sold 9,585 for $16.39, making the entire transaction worth $157,098. This insider now owns 99,293 shares in total.
TG Therapeutics Inc (TGTX) Earnings and Forecasts
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported 0.73 earnings per share (EPS) for the period topping the consensus outlook (set at 0.12) by 0.61. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -41.65% per share during the next fiscal year.
TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators
TG Therapeutics Inc (TGTX) is currently performing well based on its current performance indicators. A quick ratio of 2.83 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.88. Likewise, its price to free cash flow for the trailing twelve months is 55.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.60, a number that is poised to hit 0.02 in the next quarter and is forecasted to reach 0.74 in one year’s time.
Technical Analysis of TG Therapeutics Inc (TGTX)
Analysing the last 5-days average volume posted by the [TG Therapeutics Inc, TGTX], we can find that recorded value of 2.42 million was lower than the volume posted last year of 3.66 million. As of the previous 9 days, the stock’s Stochastic %D was 73.12%. Additionally, its Average True Range was 1.13.
During the past 100 days, TG Therapeutics Inc’s (TGTX) raw stochastic average was set at 81.87%, which indicates a significant decrease from 86.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.94% in the past 14 days, which was lower than the 57.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.21, while its 200-day Moving Average is $18.33. Now, the first resistance to watch is $24.90. This is followed by the second major resistance level at $25.44. The third major resistance level sits at $26.46. If the price goes on to break the first support level at $23.34, it is likely to go to the next support level at $22.32. Should the price break the second support level, the third support level stands at $21.78.
TG Therapeutics Inc (NASDAQ: TGTX) Key Stats
Market capitalization of the company is 3.77 billion based on 154,543K outstanding shares. Right now, sales total 233,660 K and income totals 12,670 K. The company made 73,470 K in profit during its latest quarter, and 6,880 K in sales during its previous quarter.
